---
title: "CEL-SCI Corporation (CVM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CVM.US.md"
symbol: "CVM.US"
name: "CEL-SCI Corporation"
industry: "Biotechnology"
datetime: "2026-05-20T13:58:27.997Z"
locales:
  - [en](https://longbridge.com/en/quote/CVM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CVM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CVM.US.md)
---

# CEL-SCI Corporation (CVM.US)

## Company Overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company’s LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [cel-sci.com](https://cel-sci.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.59 | 149 | - | - | - |
| PB | 1.96 | 186 | 8.66 | 3.23 | 2.27 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-07T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.55 |
| Highest Target | 25.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CVM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CVM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CVM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CVM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**